Executive Chair of $ENTG sells 345 shares in insider sale

The recent selling activity of 345 shares of $ENTG by Executive Chair, Bertrand Loy, on December 1, 2025, for an estimated $26,789 has caught the attention of investors. The transaction, disclosed through a recent SEC filing, amounted to approximately 0.1% of their shares in this class of stock, leaving Loy with ownership of 305,820 shares of $ENTG. This sale adds to a series of insider trading activities within $ENTG, with a total of seven trades conducted by insiders in the last six months, all of which have been sales, including Loy’s three sales amounting to 57,570 shares and a total of $4,425,994.

Tracking insider transactions can provide valuable insights into company movements and sentiments, and interested investors can utilize tools like Quiver Quantitative’s insider trading dashboard to monitor such activities closely. Additionally, institutional investors have also shown varying sentiments towards $ENTG in the recent quarter, with 284 institutions increasing their positions while 378 decreased theirs. Noteworthy moves include Capital Research Global Investors adding a substantial 6,974,133 shares to their portfolio, D1 Capital Partners L.P. significantly reducing their stake by 3,019,633 shares, and Baillie Gifford & Co liquidating their entire position of 2,058,007 shares in Q3 2025.

With regards to $ENTG’s financial performance, the company reported revenues of $807.1M in Q3 2025, reflecting a slight decrease of -0.07% compared to the same period the previous year. Investors keen on keeping track of $ENTG’s financials can do so through Quiver Quantitative’s dedicated stock page for the company.

In the realm of congressional stock trading, members of Congress engaged in six transactions involving $ENTG over the past six months, with two purchases and four sales. Representatives Lisa C. McClain and April McClain Delaney have been active participants in trading $ENTG shares during this period, making notable purchases and sales.

Amidst all this trading activity and movement surrounding $ENTG, Wall Street analysts have been issuing reports and ratings on the stock, with two firms issuing buy ratings and zero sell ratings. Notable analyst recommendations include an “Outperform” rating by Mizuho and an “Overweight” rating by Keybanc, providing investors with valuable insights into the stock’s potential performance and outlook.

Furthermore, multiple analysts have also assigned price targets to $ENTG in recent months, with a median target of $95.0. Analysts such as John Roberts from Mizuho, Edward Yang from Oppenheimer, Timothy Arcuri from UBS, Aleksey Yefremov from Keybanc, and James Schneider from Goldman Sachs have all provided varying price targets, offering investors a range of projections to consider in their investment decisions.

It is essential to note that the information presented in this article is not financial advice, and readers are encouraged to refer to Quiver Quantitative’s disclaimers for further information. Investors are advised to conduct thorough research and due diligence before making any investment decisions in $ENTG or any other securities.